Expression Of PS6K1 In CD133+ Epithelial Ovarian Cancer And Its Clinical Significance

Objective: Through detecting the expression of pS6K1 and CD133 in epithelial ovarian cancer tissues,we analyzed the correlation between these two proteins as well as the relationship between pS6K1 expression and clinicopathological characteristics of patients with CD133+ epithelial ovarian cancer.In order to investigate the clinical significance of the expression of pS6K1 in CD133+ epithelial ovarian cancer.Methods: Immunohistochemistry was used to detect the expression of pS6K1 and CD133 in 60 patients with epithelial ovarian cancer.The clinical data of the 60 patients were retrospectively analyzed.We used SPSS software to deal with the experimental data.Correlations between these two proteins and the clinicopathological features,such as recurrence of platinum resistance,pathological types,initial symptoms of ascites,histological differentiation,age,initial CA125 level ect.as well as prognosis,were analyzed.We also analyzed the correlation between pS6K1 and CD133.Moreover,the correlation between pS6K1 expression and PFS as well as OS of patients with CD133+EOC was analyzed.Results:1.Compared with normal ovarian tissue,the positive rate of pS6K1 expression in EOC tissues was higher significantly(70%vs15%,P=0.000).In epithelial ovarian carcinoma,there were no significant correlations of pS6K1 expression with FIGO staging,tissue differentiation,symptom of ascites,age,recurrence,platinum-resistant recurrence,lymph node metastasis,preoperative CA125 level and pathological type(P>0.05).2.Compared with normal ovarian tissue,the positive rate of CD133 expression in EOC tissues was higher significantly(63.3%vs15%,P=0.000).The expression of CD133 was correlated significantly with platinum-resistant recurrence(?2=4.429,P=0.044).There were no significant correlations with FIGO staging,tissue differentiation,symptom of ascites,age,recurrence,lymph node metastasis,preoperative CA125 level and pathological type(P>0.05).3.In EOC,pS6K1 and CD133 were positively correlated,correlation coefficient R=0.332,P=0.010.4.For PFS,univariate analysis showed that the expression of pS6K1 and CD133,FIGO stage,age,lymph node metastasis,platinum-resistant recurrence were the factors influencing PFS of epithelial ovarian cancer(P < 0.05).There were no significant correlations with to PFS with the degree of tissue differentiation,preoperative CA125 level,symptom of ascites,and pathological type(P > 0.05).Multivariate analysis showed that pS6K1 expression and platinum-resistant recurrence were independent prognostic factors of epithelial ovarian carcinoma.5.For OS,univariate analysis showed that age and platinum-resistant recurrence were the factors influencing OS of patients with epithelial ovarian cancer OS(P < 0.05),while there were no significant correlation to OS of EOC with the expression of pS6K1 and CD133,FIGO stage,ascites,tissue differentiation,lymph node metastasis,preoperative CA125 level,and pathological type(P>0.05).6.Compared with CD133-epithelial ovarian cancer,the positive rate of pS6K1 expression in CD133+ EOC was higher significantly(81.4%vs50%,P=0.010).In CD133+ epithelial ovarian cancer,positive expression of pS6K1 was correlated significantly with reduced 2-year PFS.The percentage of 2-year PFS was 88.9% in pS6K1 negative group while 50% in positive group(P=0.020).7.Co-expression of pS6K1 and CD133 was an influencing factor in PFS to patients with EOC(P < 0.05).There were no significant correlation to OS of patients with epithelial ovarian cancer with the co-expression of CD133 and pS6K1(P>0.05).The co-positive expression was correlated significantly with reduced 2-year OS.Conclusions:1.pS6K1 was high expressed in epithelial ovarian cancer,which may be involved in the tumorigenesis of EOC.2.Positive expression of CD133 was correlated with platinum-resistance recurrence in epithelial ovarian cancer.3.The expression of pS6K1 and CD133 were positively correlated in epithelial ovarian cancer.4.2-year PFS of patients with CD133+ epithelial ovarian cancer was influenced by pS6K1.5.Co-expression of pS6K1 and CD133 was a adverse factor to PFS of epithelial ovarian cancer,and influenced 2-year OS.